Hong Kong
· Delayed Price · Currency is HKD InnoCare Pharma Company Description
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases.
It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder.
The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma.
In addition, it develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases.
Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical development collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer.
InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
| Country | Cayman Islands |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,089 |
| CEO | Jisong Cui |
Contact Details
Address: Building 8 Beijing, 102206 China | |
| Phone | 86 10 6660 9999 |
| Website | innocarepharma.com |
Stock Details
| Ticker Symbol | 9969 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG4783B1032 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jisong Cui Ph.D. | Co-Founder, Chairwoman and Chief Executive Officer |
| Dr. Renbin Zhao Ph.D. | Vice President of Clinical Development and Medical Research and Executive Director |
| Xin Fu | Chief Financial Officer |
| Nan Gao | Chief Operating Officer |
| Yue Tan | Accounting Supervisor |
| Dr. Xiangyang Chen Ph.D. | Chief Technology Officer |
| Junsu Wang | General Counsel |
| Davy Ouyang Ph.D. | Vice President and Head of Biology |
| Jeff Chen | Chief Commercial Officer |
| Bei Yuan | Secretary of the Board |